Arch Therapeutics Inc (ARTH)

[Regis999]

Most of the items related to distribution or marketing will be handled by Arch's future partner---JNJ or Baxter

Look at the type of deal these companies did--imagine Arch going same for say 50 of the 200 AC5 apps

Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study (market cap $ 67 million---royalty in high teens)

"This morning, MEI $MEIP is taking the wraps off a development deal with Switzerland’s Helsinn designed to shepherd the HDAC inhibitor pracinostat through a pivotal study. MEI gets $20 million in near-term cash —$15 million up front with a $5 million milestone at the start of the Phase III — along with a $5 million equity investment. And there’s $444 million in milestones on the table for success, along with royalties that can be earned from Helsinn’s marketing efforts"


"Advaxis Inc. ADXS, +5.48% shares spiked 28% in pre-market trade Tuesday after the company announced a $40 million agreement with Amgen Inc. AMGN, -0.15% to develop and commercialize cancer immunotherapy treatment ADXS-NEO. The agreement includes a $40 million upfront payment to Advaxis and a $25 million purchase of the company's common stock by Amgen, along with sales milestone payments of up to $475 million and additional royalty payments based on global sales."